King's College London

Research portal

Candida albicans and candidalysin in inflammatory disorders and cancer

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalImmunology
Volume162
Issue number1
DOIs
Accepted/In press1 Jan 2020
PublishedJan 2021

Bibliographical note

Funding Information: J.H. conceptualised and wrote the paper; G.C. created the schematic diagram; J.G., J.P.R., N.K. and J.R.N. edited the paper. This work was supported by grants from the Wellcome Trust (214229 Z 18 Z), Biotechnology & Biological Sciences Research Council (BB/N014677/1), National Institutes of Health (R37‐DE022550), King’s Health Partners Challenge Fund (R170501), the Rosetrees Trust (M680), and the NIH Research at Guys and St. Thomas’s NHS Foundation Trust and the King’s College London Biomedical Research Centre (IS‐BRC‐1215‐20006). Publisher Copyright: © 2020 The Authors. Immunology published by John Wiley & Sons Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

Abstract

As our understanding of mycology progresses, the impact of fungal microbes on human health has become increasingly evident. Candida albicans is a common commensal fungus that gives rise to local and systemic infections, particularly in immunocompromised patients where it can result in mortality. However, C. albicans has also been quietly linked with a variety of inflammatory disorders, to which it has traditionally been considered incidental; recent studies may now provide new aspects of these relationships for further consideration. This review provides a novel perspective on the impact of C. albicans and its peptide toxin, candidalysin, on human health, exploring their contributions to pathology within a variety of diseases.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454